{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:47:45Z","timestamp":1790822865204,"version":"4.1.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PMPDP3_151323"],"award-info":[{"award-number":["PMPDP3_151323"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32-135596"],"award-info":[{"award-number":["32-135596"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["FN 33CM30-124087"],"award-info":[{"award-number":["FN 33CM30-124087"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Aims<\/jats:title>\n<jats:p>Glomerular damage indicated by proteinuria is a main symptom in diabetic nephropathy. Mineralocorticoid receptor (MR) antagonists (MRAs) are beneficial irrespective of aldosterone availability. Thus, we hypothesized an alternatively activated MR to promote glomerular damage in proteinuric diabetic nephropathy. Specifically, we aimed first to demonstrate the presence of steroid hormones serving as alternative MR targets in type II diabetic patients with proteinuric kidney disease, second whether MR selectivity was modified, third to characterize MR and glucocorticoid receptor (GR) expression and activity in glomerular cell types exposed to eu- and hyperglycemic conditions, fourth to characterize the pro-fibrotic potential of primary human renal mesangial cells (HRMC) upon stimulation with aldosterone and cortisol, and fifth to specify the involvement of the MR and\/or GR in pro-fibrotic signaling.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>Urinary steroid hormone profiles of patients with diabetic kidney disease were analyzed by gas chromatography\u2013mass spectrometry and compared to an age and gender matched healthy control group taken out of a population study. In both cohorts, the activity of the MR pre-receptor enzyme 11\u03b2-hydroxysteroid dehydrogenase type 2 (HSD11B2), which inactivates cortisol to prevent it from binding to the MR, was assessed to define a change in MR selectivity. Expression of HSD11B2, MR and GR was quantified in HRMC and primary human renal glomerular endothelial cells (HRGEC). Activity of MR and GR was explored in HRMC by measuring the MR\/GR down-stream signal SGK1 and the pro-fibrotic genes TGFB1, FN1 and COL1A1 in normal and high glucose conditions with the MR\/GR agonists aldosterone\/cortisol and the MR\/GR antagonists spironolactone\/RU486.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Patients with diabetic kidney disease excreted more tetrahydroaldosterone than the control group reaching significance in men. The excretion of MR-agonistic steroid hormones was only increased for 18-hydroxytetrahydrocorticosterone in diabetic women. The excretion of most glucocorticoids was higher in the diabetic cohort. Higher apparent systemic HSD11B2 activity suggested less activation of the MR by cortisol in diabetic patients. Both cell types, HRMC and HRGEC, lacked expression of HSD11B2. Hyperglycemic conditions did not change MR and GR expression and activity. Stimulation with both aldosterone and cortisol promoted upregulation of pro-fibrotic genes in HRMC. This effect of MR and\/or GR activation was more pronounced in high glucose conditions and partially inhibited by MRAs and GR antagonists.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In patients with diabetic kidney disease alternative MR activation is conceivable as cortisol and cortisone metabolites are increased. Systemic availability of active metabolites is counteracted via an increased HSD11B2 activity. As this cortisol deactivation is absent in HRMC and HRGEC, cortisol binding to the MR is enabled. Both, cortisol and aldosterone stimulation led to an increased expression of pro-fibrotic genes in HRMC. This mechanism was related to the MR as well as the GR and more marked in high glucose conditions linking the benefit of MRAs in diabetic kidney disease to these findings.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0269920","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T17:32:34Z","timestamp":1656091954000},"page":"e0269920","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Increased glucocorticoid metabolism in diabetic kidney disease"],"prefix":"10.1371","volume":"17","author":[{"given":"Daniel","family":"Ackermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Bochud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Burnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Paccaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idris","family":"Guessous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Ponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno","family":"Pruijm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Pech\u00e8re-Bertschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Jamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahel","family":"Klossner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus G.","family":"Mohaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-5935","authenticated-orcid":true,"given":"Carine","family":"Gennari-Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"issue":"12","key":"pone.0269920.ref001","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities.","volume":"12","author":"RZ Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"pone.0269920.ref002","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/HYPERTENSIONAHA.115.07074","article-title":"Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors.","volume":"67","author":"M Briet","year":"2016","journal-title":"Hypertension"},{"issue":"3","key":"pone.0269920.ref003","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.113.02581","article-title":"Mineralocorticoid receptor, the main player in aldosterone-induced large artery stiffness","volume":"63","author":"M. Briet","year":"2014","journal-title":"Hypertension"},{"issue":"2","key":"pone.0269920.ref004","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm1545","article-title":"Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity","volume":"13","author":"JA Leopold","year":"2007","journal-title":"Nat Med"},{"issue":"4","key":"pone.0269920.ref005","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2014.348","article-title":"Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans","volume":"87","author":"K Hosoya","year":"2015","journal-title":"Kidney Int"},{"issue":"2","key":"pone.0269920.ref006","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/eurheartj\/ehr176","article-title":"Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure","volume":"33","author":"F Ivanes","year":"2012","journal-title":"Eur Heart J"},{"issue":"11","key":"pone.0269920.ref007","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1681\/ASN.V10112382","article-title":"The paradox of the low-renin state in diabetic nephropathy","volume":"10","author":"DA Price","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"pone.0269920.ref008","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability","volume":"45","author":"A Nishiyama","year":"2005","journal-title":"Hypertension"},{"issue":"2","key":"pone.0269920.ref009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"J Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"pone.0269920.ref010","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1111\/j.1440-1797.2005.00455.x","article-title":"Role of aldosterone in diabetic nephropathy.","volume":"10","author":"DR Cha","year":"2005","journal-title":"Nephrology (Carlton)."},{"issue":"10","key":"pone.0269920.ref011","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"M Quinkler","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"pone.0269920.ref012","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"EL Greene","year":"1996","journal-title":"J Clin Invest"},{"issue":"5","key":"pone.0269920.ref013","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"ER Blasi","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"pone.0269920.ref014","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/en.2002-220956","article-title":"Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes","volume":"144","author":"TY Chun","year":"2003","journal-title":"Endocrinology"},{"issue":"Suppl","key":"pone.0269920.ref015","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.3346\/jkms.2009.24.S1.S195","article-title":"Aldosterone-induced TGF-beta1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells.","volume":"24","author":"JS Han","year":"2009","journal-title":"J Korean Med Sci."},{"issue":"4","key":"pone.0269920.ref016","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11906-011-0202-2","article-title":"Mineralocorticoid receptor blockade in chronic kidney disease","volume":"13","author":"MJ Volk","year":"2011","journal-title":"Curr Hypertens Rep"},{"issue":"23","key":"pone.0269920.ref017","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"GL Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0269920.ref018","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"A Sato","year":"2003","journal-title":"Hypertension"},{"issue":"4","key":"pone.0269920.ref019","doi-asserted-by":"crossref","first-page":"H1351","DOI":"10.1152\/ajpheart.01186.2004","article-title":"Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure","volume":"289","author":"T Karram","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"11","key":"pone.0269920.ref020","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"C Guo","year":"2006","journal-title":"Endocrinology"},{"issue":"5","key":"pone.0269920.ref021","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.","volume":"50","author":"GL Bakris","year":"2019","journal-title":"Am J Nephrol."},{"issue":"9","key":"pone.0269920.ref022","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial","volume":"314","author":"GL Bakris","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"pone.0269920.ref023","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"S Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"31","key":"pone.0269920.ref024","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"B Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"6","key":"pone.0269920.ref025","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"CG Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"issue":"22","key":"pone.0269920.ref026","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","article-title":"Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone","volume":"106","author":"P Lacolley","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"pone.0269920.ref027","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"D Fraccarollo","year":"2011","journal-title":"Circulation"},{"issue":"9731","key":"pone.0269920.ref028","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis C","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"pone.0269920.ref029","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"B Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0269920.ref030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.","volume":"50","author":"LM Ruilope","year":"2019","journal-title":"Am J Nephrol."},{"key":"pone.0269920.ref031","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone","author":"R Agarwal","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"pone.0269920.ref032","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/HJH.0b013e32834103a9","article-title":"Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats","volume":"29","author":"K Rafiq","year":"2011","journal-title":"J Hypertens"},{"issue":"6","key":"pone.0269920.ref033","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.2012.170","article-title":"Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury","volume":"82","author":"JM Luther","year":"2012","journal-title":"Kidney Int"},{"issue":"2","key":"pone.0269920.ref034","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000077396","article-title":"Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME\/SHR model.","volume":"24","author":"X Zhou","year":"2004","journal-title":"Am J Nephrol"},{"issue":"12","key":"pone.0269920.ref035","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1291\/hypres.27.971","article-title":"Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.","volume":"27","author":"M Asai","year":"2004","journal-title":"Hypertens Res"},{"issue":"6","key":"pone.0269920.ref036","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.109.136242","article-title":"Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction","volume":"54","author":"AS Mihailidou","year":"2009","journal-title":"Hypertension"},{"issue":"10","key":"pone.0269920.ref037","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1210\/en.2007-0209","article-title":"Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid\/salt administration?","volume":"148","author":"AJ Rickard","year":"2007","journal-title":"Endocrinology"},{"issue":"9","key":"pone.0269920.ref038","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"MG Usher","year":"2010","journal-title":"J Clin Invest"},{"issue":"3","key":"pone.0269920.ref039","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"AJ Rickard","year":"2009","journal-title":"Hypertension"},{"issue":"3","key":"pone.0269920.ref040","doi-asserted-by":"crossref","first-page":"e0214549","DOI":"10.1371\/journal.pone.0214549","article-title":"Reference intervals for the urinary steroid metabolome: The impact of sex, age, day and night time on human adult steroidogenesis.","volume":"14","author":"D Ackermann","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"pone.0269920.ref041","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajh\/hpv138","article-title":"CYP17A1 Enzyme Activity Is Linked to Ambulatory Blood Pressure in a Family-Based Population Study","volume":"29","author":"D Ackermann","year":"2016","journal-title":"Am J Hypertens"},{"key":"pone.0269920.ref042","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12916-015-0275-x","article-title":"New anthropometry-based age- and sex-specific reference values for urinary 24-hour creatinine excretion based on the adult Swiss population.","volume":"13","author":"V Forni Ogna","year":"2015","journal-title":"BMC Med"},{"issue":"1\u20133","key":"pone.0269920.ref043","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0960-0760(93)90132-G","article-title":"Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research","volume":"45","author":"CH Shackleton","year":"1993","journal-title":"The Journal of steroid biochemistry and molecular biology"},{"issue":"6","key":"pone.0269920.ref044","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/j.1523-1755.2004.66031.x","article-title":"Evidence for compromised aldosterone synthase enzyme activity in preeclampsia","volume":"66","author":"K Shojaati","year":"2004","journal-title":"Kidney Int"},{"issue":"2","key":"pone.0269920.ref045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2337\/db12-0905","article-title":"Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?","volume":"62","author":"SB Bender","year":"2013","journal-title":"Diabetes"},{"issue":"2","key":"pone.0269920.ref046","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.ackd.2014.08.003","article-title":"Aldosterone blockade in CKD: emphasis on pharmacology","volume":"22","author":"MH Schwenk","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"issue":"14","key":"pone.0269920.ref047","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.steroids.2011.09.010","article-title":"Increased urinary glucocorticoid metabolites are associated with metabolic syndrome, hypoadiponectinemia, insulin resistance and beta cell dysfunction","volume":"76","author":"R Baudrand","year":"2011","journal-title":"Steroids"},{"issue":"12","key":"pone.0269920.ref048","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1210\/jc.2002-020048","article-title":"Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance","volume":"87","author":"RC Andrews","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0269920.ref049","doi-asserted-by":"crossref","first-page":"427640","DOI":"10.1155\/2013\/427640","article-title":"Chronic inhibition of 11 beta -hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulin resistance, and hypertriglyceridemia in metabolic syndrome","volume":"2013","author":"CG Schnackenberg","year":"2013","journal-title":"Biomed Res Int"},{"issue":"7","key":"pone.0269920.ref050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1210\/js.2018-00088","article-title":"Lower Renal Function Is Associated With Derangement of 11-beta Hydroxysteroid Dehydrogenase in Type 2 Diabetes.","volume":"2","author":"CM Gant","year":"2018","journal-title":"J Endocr Soc"},{"issue":"6","key":"pone.0269920.ref051","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1210\/en.2009-1476","article-title":"Activation of mineralocorticoid receptors by exogenous glucocorticoids and the development of cardiovascular inflammatory responses in adrenalectomized rats","volume":"151","author":"MJ Young","year":"2010","journal-title":"Endocrinology"},{"issue":"2","key":"pone.0269920.ref052","first-page":"877","article-title":"11beta-hydroxysteroid dehydrogenase type 2 is expressed in the human kidney glomerulus","volume":"87","author":"S Kataoka","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"pone.0269920.ref053","doi-asserted-by":"crossref","first-page":"F1381","DOI":"10.1152\/ajprenal.00101.2009","article-title":"Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions","volume":"297","author":"SH Lee","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"issue":"8","key":"pone.0269920.ref054","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1681\/ASN.2005020129","article-title":"Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1\/2, cyclin D1, and cyclin A","volume":"16","author":"Y Terada","year":"2005","journal-title":"J Am Soc Nephrol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T17:33:18Z","timestamp":1656091998000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269920"}},"subtitle":[],"editor":[{"given":"Norma A.","family":"Bobadilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0269920","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]}}}